Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + cetuximab + RT vs SOC in LA SCCHN
NCT02999087Phase 3Active, not recruiting
- Sponsor
- GORTEC
- Start
- Sep 2017
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of avelumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by GORTEC. Started Sep 2017; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02999087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999087.